CASPR2 antibody-associated neurological syndrome after PD-1 inhibitor treatment (tislelizumab) in a patient with lung adenocarcinoma: A case report and literature review.
Immune checkpoint inhibitors (ICIs) have significantly improved survival in patients with advanced lung cancer. However, they can induce immune-related adverse events (irAEs), including neurological complications such as protein-like 2 (CASPR2) antibody-associated neurological syndromes. This form of autoimmune neuroim...